Trademark Overview
On Friday, April 25, 2025, a trademark application was filed for OPTILEUKIN with the United States Patent and Trademark Office. The USPTO has given the OPTILEUKIN trademark a serial number of 99155128. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, October 1, 2025. This trademark is owned by InVitria, Inc.. The OPTILEUKIN trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:
Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for medical or veterinary purposes; Recombinant cytokine proteins for use as cell growth media for growing cells for clinical use; Recombinant cytokine proteins for use as reagents for clinical medical purposes; Recombinant cytokine protein arrays for clinical medical diagnosis purposes; Recombinant cytokine proteins sold as a component ingredient of therapeutic pharmaceuticals for the treatment of immune system related diseases and disorders; Recombinant cytokine proteins for use as reagents for medical use, for the optimization of in vitro expansion of cells; Pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cells
Recombinant cytokine proteins in raw material form for scientific and medical research use; Recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific and research use; Non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific, laboratory and medical research
